IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial
Wong, Ka Sing Lawrence1; Hu, Dai Yi2; Oomman, Abraham3; Tan, Ru-San4; Patel, Manesh R.5; Singer, Daniel E.7,8; Breithardt, Guenter9; Mahaffey, Kenneth W.5; Becker, Richard C.5; Califf, Robert6; Fox, Keith A. A.10,11; Berkowitz, Scott D.12; Hacke, Werner13; Hankey, Graeme J.14; Executive Steering Comm; ROCKET AF Study Investigators
关键词atrial fibrillation Far East rivaroxaban stroke
刊名STROKE
2014-06-01
DOI10.1161/STROKEAHA.113.002968
45期:6页:1739-+
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Clinical Neurology ; Peripheral Vascular Disease
研究领域[WOS]Neurosciences & Neurology ; Cardiovascular System & Cardiology
关键词[WOS]ATRIAL-FIBRILLATION ; JAPANESE PATIENTS ; WARFARIN ; ANTICOAGULATION ; THERAPY ; CHINA ; PHARMACODYNAMICS ; PHARMACOKINETICS ; INTENSITY ; SUBTYPES
英文摘要

Background and Purpose-In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants.

Methods-Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed.

Results-A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point (stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867).

Conclusions-Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation.

语种英语
WOS记录号WOS:000337090700034
资助机构Janssen Research and Development, LLC ; Bayer HealthCare Pharmaceuticals
引用统计
被引频次:53[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64784
专题北京大学第二临床医学院
作者单位1.Harvard Univ, Sch Med, Boston, MA USA
2.Univ Hosp Munster, Dept Cardiovasc Med, Munster, Germany
3.Bayer HealthCare Pharmaceut, Montville, NJ USA
4.Heidelberg Univ, Dept Neurol, Heidelberg, Germany
5.Apollo Hosp, Dept Cardiol, Madras, Tamil Nadu, India
6.Natl Heart Ctr, Singapore, Singapore
7.Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA
8.Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
9.Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China
10.Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Clin Res Inst, Durham, NC 27710 USA
11.Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Translat Med Inst, Durham, NC 27710 USA
12.Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland
13.Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland
14.Univ Western Australia, Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6009, Australia
推荐引用方式
GB/T 7714
Wong, Ka Sing Lawrence,Hu, Dai Yi,Oomman, Abraham,et al. Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial[J]. STROKE,2014,45(6):1739-+.
APA Wong, Ka Sing Lawrence.,Hu, Dai Yi.,Oomman, Abraham.,Tan, Ru-San.,Patel, Manesh R..,...&ROCKET AF Study Investigators.(2014).Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial.STROKE,45(6),1739-+.
MLA Wong, Ka Sing Lawrence,et al."Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial".STROKE 45.6(2014):1739-+.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wong, Ka Sing Lawrence]的文章
[Hu, Dai Yi]的文章
[Oomman, Abraham]的文章
百度学术
百度学术中相似的文章
[Wong, Ka Sing Lawrence]的文章
[Hu, Dai Yi]的文章
[Oomman, Abraham]的文章
必应学术
必应学术中相似的文章
[Wong, Ka Sing Lawrence]的文章
[Hu, Dai Yi]的文章
[Oomman, Abraham]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。